BerGenBio ASA (FRA:7BG0)
€ 0.708 0.009 (1.29%) Market Cap: 28.14 Mil Enterprise Value: 13.42 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 58/100

Q3 2023 Bergenbio ASA Earnings Call Transcript

Nov 14, 2023 / 09:00AM GMT
Release Date Price: €1.4 (+0.72%)
Martin Olin BerGenBio ASA;CEO

Good morning. My name is Martin Olin. And with me today, I have Cristina Oliva, the Chief Medical Officer of BerGenBio. Today, we will provide you with an update on our business and our Q3 financial report. And we will provide you with some insight into what we consider to be a very novel approach to address a significant unmet medical need in non-small cell lung cancer.

I'll just remind the audience about the formalities and forward-looking statements.

So to recap, BerGenBio -- what we're doing -- it is known that AXL, a cell surface protein, plays a key role in the progression of cancer, including non-small cell lung cancer. And we are focused entirely on developing our lead compound, bemcentinib, for selective inhibition of AXL to delay chemoresistance and also potentiate immunotherapy in non-small cell lung cancer, two of the known pure prognostic factors in a large subset of non-small cell lung cancer patients that, today, doesn't respond very well to standard of care, which consists of chemotherapy and immune checkpoint inhibition.

We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot